Cellectis S.A. (CLLS) vs Milestone Pharmaceuticals Inc. (MIST)

Cellectis S.A. and Milestone Pharmaceuticals Inc. are both Biotechnology companies. Cellectis S.A. and Milestone Pharmaceuticals Inc. are of similar size ($103.4M and $99.0M). Cellectis S.A. has the higher net margin (−102.3% vs −1,586.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Cellectis S.A. leads on 11 and Milestone Pharmaceuticals Inc. on 4.

Valuation

Metric CLLS MIST Biotechnology median
P/E n/m n/m 7.88
P/S 2.32 20.68 11.47
P/B 3.60 6.01 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.02 0.74
EV/Sales 0.86 (0.35) 10.73
Earnings yield (44.50%) (87.34%) (28.84%)
Free cash flow yield (31.23%) (56.26%) (23.03%)

Profitability

Metric CLLS MIST Biotechnology median
Gross margin 100.00% 13.27% 65.16%
Operating margin (90.88%) (1,479.69%) 0.00%
Net margin (102.34%) (1,586.01%) 0.00%
Free cash flow margin (68.63%) (1,163.79%) 0.00%
Return on equity (94.54%) (35,522.62%) (57.72%)
Return on assets (21.02%) (73.36%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLLS MIST Biotechnology median
Revenue growth (TTM) 0.61% — 5.64%
EPS growth (last fiscal year) (63.41%) (11.94%) —
Revenue growth, 5-year CAGR (0.70%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLLS MIST Biotechnology median
Debt to equity 1.79 3.25 0.00
Current ratio 1.37 8.13 4.73
Net debt to EBITDA 9.54 0.79 0.96

Dividend

Metric CLLS MIST Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CLLS MIST Biotechnology median
Market cap 103.43m 98.96m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack